Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease

被引:159
作者
Ho, L
Purohit, D
Haroutunian, V
Luterman, JD
Willis, F
Naslund, J
Buxbaum, JD
Mohs, RC
Aisen, PS
Pasinetti, GM
机构
[1] CUNY Mt Sinai Sch Med, Neuroinflammat Res Labs, New York, NY 10029 USA
[2] CUNY Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA
[3] CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA
[4] Karolinska Inst, Dept Clin Neurosci, Huddinge, Sweden
[5] Georgetown Univ, Dept Neurol, Med Ctr, Washington, DC USA
关键词
D O I
10.1001/archneur.58.3.487
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Prior studies have shown that. cyclooxygenase 2 (COX-2), an enzyme involved in inflammatory mechanisms and neuronal activities, is up-regulated in the brain with Alzheimer disease (AD) and may represent a therapeutic target for anti-inflammatory treatments. Objective: To explore COX-2 expression in the brain as a function of clinical progression of early AD. Design and Main Outcome Measures: Using semi-quantitative immunocytochemistry, we analyzed COX-2 protein content in the hippocampal formation in 54 post-mortem brain specimens from patients with normal or impaired cognitive status. Setting and Patients: Postmortem study of nursing home residents. Results: The immunointensity of COX-2 signal in the CA3 and CA2 but not CA1 subdivisions of the pyramidal layers of the hippocampal formation of the AD brain increased as the disease progressed from questionable to mild clinical dementia as assessed by Clinical Dementia Rating. COX-2 signal was increased in all 3 regions examined among cases characterized by severe dementia. Conclusion: Neuronal COX-2 content in subsets of hippocampal pyramidal neurons may be an indicator of progression of dementia in early AD.
引用
收藏
页码:487 / 492
页数:6
相关论文
共 18 条
[1]  
Bancroft JD., 1997, THEORY PRACTICE HIST
[2]   Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease [J].
Haroutunian, V ;
Perl, DP ;
Purohit, DP ;
Marin, D ;
Khan, K ;
Lantz, M ;
Davis, KL ;
Mohs, RC .
ARCHIVES OF NEUROLOGY, 1998, 55 (09) :1185-1191
[3]  
Ho L, 1999, J NEUROSCI RES, V57, P295
[4]   Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2 [J].
Kelley, KA ;
Ho, L ;
Winger, D ;
Freire-Moar, J ;
Borelli, CB ;
Aisen, PS ;
Pasinetti, GM .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (03) :995-1004
[5]   Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies [J].
McGeer, PL ;
Schulzer, M ;
McGeer, EG .
NEUROLOGY, 1996, 47 (02) :425-432
[6]   The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: A commentary [J].
Mirra, SS .
NEUROBIOLOGY OF AGING, 1997, 18 (04) :S91-S94
[7]   NEUROPATHOLOGICAL BACKGROUND OF 27 CENTENARIAN BRAINS [J].
MIZUTANI, T ;
SHIMADA, H .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1992, 108 (02) :168-177
[8]   THE CLINICAL DEMENTIA RATING (CDR) - CURRENT VERSION AND SCORING RULES [J].
MORRIS, JC .
NEUROLOGY, 1993, 43 (11) :2412-2414
[9]   Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline [J].
Näslund, J ;
Haroutunian, V ;
Mohs, R ;
Davis, KL ;
Davies, P ;
Greengard, P ;
Buxbaum, JD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (12) :1571-1577
[10]   Induction of cyclo-oxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: Specific localization in affected neurones and axons [J].
Oka, A ;
Takashima, S .
NEUROREPORT, 1997, 8 (05) :1161-1164